DWA
ZYNE

Dorsey Wright & Associates’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Dorsey Wright & Associates’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-804
Closed -$11K – 341
2019
Q2 		$11K Buy
+804
New +$9.28K ﹤0.01% 243

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dorsey Wright & Associates's ZYNE Position: Q3 2019 in Review

Dorsey Wright & Associates sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2019, closing a stake of 804 shares — an estimated $11K sold.

Dorsey Wright & Associates first reported a position in ZYNE in Q2 2019 and held it in 1 quarter. The position peaked at $11K in Q2 2019. 84 funds tracked by Wall St. Rank hold ZYNE as of Q3 2019.

  • Dorsey Wright & Associates reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
  • Dorsey Wright & Associates sold 804 Zynerba Pharmaceuticals, Inc shares in Q3 2019, an estimated $11K.
  • Dorsey Wright & Associates first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 1 quarter.
  • Dorsey Wright & Associates's Zynerba Pharmaceuticals, Inc position peaked at $11K in Q2 2019.
  • 84 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2019.

Based on Dorsey Wright & Associates's 13F filing for Q3 2019, filed 31 Oct 2019.